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Several independent studies show that accumulation of β-amyloid (Aβ) peptides, one
of the characteristic hallmark of Alzheimer’s Disease (AD), can affect normal neuronal
activity in different ways. However, in spite of intense experimental work to explain the
possible underlying mechanisms of action, a comprehensive and congruent understanding
is still lacking. Part of the problem might be the opposite ways in which Aβ have been
experimentally found to affect the normal activity of a neuron; for example, making a
neuron more excitable (by reducing the A- or DR-type K+ currents) or less excitable
(by reducing synaptic transmission and Na+ current). The overall picture is therefore
confusing, since the interplay of many mechanisms makes it difficult to link individual
experimental findings with the more general problem of understanding the progression
of the disease. This is an important issue, especially for the development of new drugs
trying to ameliorate the effects of the disease. We addressed these paradoxes through
computational models. We first modeled the different stages of AD by progressively
modifying the intrinsic membrane and synaptic properties of a realistic model neuron,
while accounting for multiple and different experimental findings and by evaluating the
contribution of each mechanism to the overall modulation of the cell’s excitability. We then
tested a number of manipulations of channel and synaptic activation properties that could
compensate for the effects of Aβ. The model predicts possible therapeutic treatments in
terms of pharmacological manipulations of channels’ kinetic and activation properties. The
results also suggest how and which mechanisms can be targeted by a drug to restore the
original firing conditions.
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INTRODUCTION
Alzheimer’s Disease (AD) is one of the most common neu-
rodegenerative disorders associated with memory deficits and
cognitive decline leading to elderly dementia (Selkoe, 1999;
Brookmeyer et al., 2007). It is well known that it mainly
involves structural alterations in the CA1 region of hippocam-
pus (Goedert, 1987; Hasselmo, 1997; Schenk et al., 1999) and
it is characterized by neuronal loss, intracellular neurofibrillary
tangles (NFT), and extracellular neuritic plaques (Nagy et al.,
1995), whose major constituent are Aβ peptides (Iwatsubo et al.,
1994), secreted after cleavage of a single transmembrane precur-
sor, termed amyloid precursor protein (APP). Despite persistent
research efforts to understand the molecular events leading to
AD, the causes of the disease are not understood. Several aspects
have been implicated in AD pathogenesis. Mechanisms such
as synaptic loss (Hamos et al., 1989; Terry et al., 1991; Terry,
2000; Knobloch and Mansuy, 2008), mitochondria dysfunction
(Moreira et al., 2001; Manczak et al., 2006; Eckert et al., 2008;
Reddy and Beal, 2008), network instability (Palop and Mucke,
2010), disregulation in calcium homeostasis (Mattson and Chan,
2001), alterations of some ionic channels, astrocytic response to
plaque deposition (Kuchibhotla et al., 2009), amyloid angiopathy
(Rensink et al., 2003), and alteration in the function of N-methyl-
D-aspartic acid (NMDA) receptors (Snyder et al., 2005; Shankar
et al., 2007; Sato et al., 2008; Texidó et al., 2011) have all been
reported to be affected by Aβ deposition on neuronal membrane.
However, it is very difficult to understand the roles, interactions,
and contribution of these disparate mechanisms to the overall
picture of the disease. A partial source of confusion could be that
experimental studies are usually carried out to isolate the effects
of a single mechanism, and/or on transgenic mouse models with
unknown compensatory effects. This may lead to a set of results
that could be conflicting (Good et al., 1996; Plant et al., 2006;
Rui et al., 2006; Kerrigan et al., 2008; Kloskowska et al., 2008) or
difficult to interpret.
In the present study, we were interested in investigating how
modifications of the synaptic and membrane properties caused
by Aβ accumulation can affect the main firing properties of
a neuron. To this purpose, we used a realistic computational
model of a hippocampal CA1 pyramidal neuron including the
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electrophysiological effects of Aβ on neuronal membrane, mod-
eled according to different independent experimental studies.
With this model, we were able to make experimentally testable
predictions on the contribution of each mechanism to the overall
modulation of the cell’s excitability, and point out possible tar-
gets for therapeutic treatments that could be used to restore the
original firing conditions.
MATERIALS AND METHODS
All simulations were implemented using v7.2 of the NEURON
simulation environment (Hines and Carnevale, 1997). Most sim-
ulations were carried out on a parallel computer system using up
to 200 processors (IBM Linux cluster, CINECA, and Bologna).
The model and simulation files specifically used for this work are
available for public download under the ModelDB section of the
Senselab database (http://senselab.med.yale.edu).
In all simulations we used the cell 5038804, a hippocampal
CA1 pyramidal neuron originally downloaded from the pub-
lic archive www.neuromorpho.org, composed by 173 membrane
sections modeled with 559 segments. The set of passive prop-
erties, voltage-dependent ionic channels, and their kinetics and
distribution were identical to those in (Migliore et al., 2008,
ModelDB a. n.87535). In this model, already validated against
a number of different experimental findings on electrophys-
iological and synaptic integration properties of CA1 neurons
(e.g., Migliore, 2003; Gasparini et al., 2004), sodium (INa) and
delayed rectifier potassium (KDR) conductances were uniformly
distributed throughout the dendrites, whereas KA and Ih conduc-
tances linearly increased with distance from soma.
To model synaptic activation, two sets of 50 AMPA excitatory
synapses (modeled as a double exponential conductance change
with 0.5 and 3ms for rise and decay time, respectively) were ran-
domly distributed in the distal (>300μm from soma) and in
the proximal apical region (Figure 1A). We used the same peak
synaptic conductance for all proximal synapses, testing several
different values in the range 0.9–2 nS. To take into account exper-
imental findings, distal synapses were three times weaker than
proximal ones (Megìas et al., 2001). Their activation time was
FIGURE 1 | Model setup. (A) Schematic representation of the hippocampal
CA1 pyramidal neuron used in all simulations (cell 5038804 in the
neurophorpho.org public archive). Red circles represent a typical distribution
of the 100 excitatory synapses, randomly redistributed and activated during
each simulation, used to calculate the average spike probability;
(B) Aβ-peptides progressive accumulation was modeled by modifying the
intrinsic active and synaptic properties of increasing membrane area; the
panels represent the control conditions (left, healthy) and typical cases where
30% (middle) or 90% (right) of membrane was affected by Aβ.
(C) Typical somatic membrane potential at three different stages of
disease (30–60–90% of impaired membrane area) during activations of
synaptic inputs (1.20 nS). Traces show the results for 10 different
simulations using a random redistribution of synaptic locations, affected
dendrites and synaptic activation times. Note the lower number of
spikes (i.e., lower spike probability) as the membrane area affected by Aβ
increases.
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drawn from a Gaussian distribution with a standard deviation
of 5ms (corresponding to the positive sweep of a γ-cycle), and
the distal set of synapses were activated with a 5ms delay with
respect to the proximal ones [to take into account the physio-
logical delay between the Perforant Path and Schaeffer Collaterals
pathways, see Migliore (2003)]. Average control conditions for the
spike probability of the neuron were calculated from 100 simula-
tions, randomly redistributing synaptic locations and activation
times. NMDA and inhibitory synapses were not included in the
model. For NMDA synapses, their properties and kinetics suggest
that they would not change the qualitative results obtained for
the relatively simple stimulation protocol used in our simulations,
i.e., single synaptic activations. For inhibitory synapses, there is
not enough information on the effects of Aβ on the interneurons
responsible for feedforward inhibition to implement a reasonable
model. A more detailed analysis of their actual role under our
stimulation conditions was thus considered outside the scope of
this paper.
To model Alzheimer effects, randomly chosen sections of
membrane composing a given portion of the total somato-
dendritic membrane area were selected, as schematically
represented in Figure 1B. Their properties were then modified
according to experimental findings: in those compartments, KA
current peak conductance was reduced by 60% (Good et al.,
1996),KDR by 40% (Good et al., 1996), andNa by 50% (Kim et al.,
2007), whereas the peak synaptic conductance of any input target-
ing an affected compartment was decreased by 50% (Kamenetz
et al., 2003; Parameshwaran et al., 2007; Wei et al., 2010; Perez-
Cruz et al., 2011). At each stage of the disease (0–100% of affected
membrane), the spike probability was calculated from a set of 100
simulations, randomly redistributing the affected compartments,
synaptic distribution, and activation times.
It may be questioned that we did not implement the effects
of Aβ on calcium channels. The reason for this choice was
that experimental findings in this case are somewhat contradic-
tory and unclear. As observed by Rui et al. (2006) most of the
confusion could be due to the fact that different kinds of Aβ frag-
ments (e.g., Aβ25−35, Aβ1−40, or Aβ1−42) could affect in different
ways the various cellular mechanisms involved in calcium regula-
tion (different types of Ca2+ channels or pumps). For example,
they observed that Aβ1−42 inhibits Ca2+ oscillations. However,
Kloskowska et al. (2008) showed, in hippocampal neurons from
an AD transgenic rat, that high levels of Aβ can instead increase
their frequency with respect wild-type neurons. Nevertheless, we
carried out a set of preliminary test simulations including differ-
ent types of calcium currents. Consistent with the results obtained
by Zou et al. (2011) the overall cell’s excitability did not change
significantly, so we decided not to consider Ca++ channels in our
model in this study.
RESULTS
We focused our attention on how AD progression can affect
the probability of a neuron reaching spike threshold following
a synaptic stimulation. Given the low averaging firing rate of
these neurons in vivo (Csicsvari et al., 1999) individual spikes
carry high information content, so this is one of the major
factors to test under pathological conditions. Figure 1C shows
typical recordings of somatic membrane potential during 10
different simulations, for three different amounts of impaired
area (i.e., 30, 60, and 90%) and for 1 nS synapes (0.3 in dis-
tal compartments). The neuron’s excitability decreases with the
amount of membrane affected, when all mechanisms are taken
into account. This effect is summarized in Figure 2, where we
show the spike probability as a function of the Aβ-affected mem-
brane for three values of synaptic conductance [0.94 nS (green),
1.00 nS (black), and 1.20 nS (red)]. The results show that, inde-
pendent of synaptic strength, the overall effect of progressive Aβ
accumulation on the neuron’s membrane is to depress neuronal
excitability.
CONTRIBUTION OF INDIVIDUAL CURRENTS
To evaluate the role of each channel to the overall effect of AD,
we started from the results with 1 nS inputs corresponding to
a medium stimulation strength that elicited a spike in about
50% of the cases. Results are shown in Figure 3, with patho-
logical conditions (i.e., including all Aβ effects) represented by
the black curve. The model suggested that the experimentally
observed reduction in only the Na+ current (Figure 3, red) or
only the synaptic inputs (Figure 3, yellow) would account for the
whole effect of AD on spike probability (Figure 3, compare red
and yellow with black). Instead, a decrease in KDR current only
(Figure 3, brown) does not influence the spike probability of a
healthy neuron (i.e., it is approximately the same independently
of the affected membrane). In striking contrast, and in agree-
ment with a previous model (Morse et al., 2010), by modifying
only the KA current (Figure 3, blue) the neuron becomes much
more excitable. This excitatory effect persists even when cou-
pled with the Na+ reduction (Figure 3, pink). Interestingly, the
simultaneous modification of the synaptic weights and KA cur-
rent (Figure 3, green) balanced their opposite effects, leading to
FIGURE 2 | Progressive effects of Aβ. Spike probability as a function of the
portion of membrane area affected by Aβ, and for three different values of
peak synaptic conductance: 0.94 nS (green), 1 nS (black), and 1.20 nS (red).
Spike probability (±s.e.m.) was calculated from a set of 100 simulations
with random redistribution of synaptic locations, affected dendrites, and
synaptic activation times.
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FIGURE 3 | Individual contribution of membrane mechanisms to the
overall effect of Aβ. Control curve (black) is the result obtained, for 1 nS
synapses, by the combined effect of Aβ on peak channel conductance [KA
(−60%), KDR (−40%), Na (−50%)], and peak synaptic conductance
(−50%); (blue) effect of KA reduction only; (red) reduction of Na current
only; (pink) KA reduction combined with Na reduction; (yellow ) reduction of
synaptic input only; (brown) reduction of KDR only; (green) combined
reduction of KA and synaptic conductance.
a spike probability close to the healthy case (i.e., the value at 0%
of affected membrane). These results suggest that the patholog-
ical modulation of each type of conductance can contribute to
the overall effect in different quantitatively and qualitatively ways,
and that an appropriate KA pharmacological manipulation could
compensate the negative effects of Aβ on the synaptic inputs.
KA PHARMACOLOGICAL MANIPULATIONS AS POSSIBLE
TREATMENT OF AD EFFECTS
We next tested whether it was possible to restore a neuron affected
by AD to the spiking probability of a healthy neuron with a drug
targeting one or more specific membrane mechanisms. This is
possible, in principle, since there are drugs that selectively act on
specific channels (discussed in Ferrante et al., 2008). We started
from an AD-affected neuron and further reduced the KA by
40%. In Figure 4 we show typical simulation findings for somatic
recordings during 10 simulations using different amounts of
affected membrane before and after this “KA treatment”. As can
be seen, in the untreated neuron case (Figure 4, top) the num-
ber of spikes decreased with the amount of affected membrane,
whereas the same number of APs was obtained in all cases after
treatment (Figure 4, bottom). These results demonstrate that it
could be possible to manipulate a single type of channel to restore
healthy conditions.
FIGURE 4 | A decrease of the KA current counterbalances the effect of AD. (A) Somatic membrane potential from 10 simulations with different amount of
membrane affected by AD. (B) Results after a 40% reduction of KA.
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This kind of treatment was then tested on the entire range of
synaptic input strengths. As shown in Figure 5, a single manipu-
lation of the KA current (a 40% reduction, on top of the already
reduced value caused by AD) was able to obtain a spiking proba-
bility that was similar to healthy conditions in all cases (Figure 5,
compare solid with dotted lines of the same color).
To evaluate the efficacy and how generalizable this kind of
treatment could be, with each combination of synaptic input
strength and amount of affected membrane, we calculated the
ratio between the spike probabilities obtained under healthy (0%
of membrane affected by AD) and damaged membrane condi-
tions (Figure 6). A ratio close to one (Figure 6, yellow areas)
FIGURE 5 | KA current reduction counterbalances the inhibitory effect
of AD in spite of the increasing Aβ accumulation. Results from
AD-neuron (solid lines) compared with the results after KA treatment for
three different strengths of synaptic input. Average (±s.e.m.) values
calculated from 100 simulations.
is typical of a condition in which the firing properties are not
affected by the progression of the disease whereas a low ratio indi-
cates a depressed neuronal activity, typical of AD. The average
results for a healthy neuron, grouped in 11 trials (Figure 6, “I” to
“XI”, each composed by 100 simulations) are plotted in Figure 6A,
and show a ratio of one for most values of synaptic input. The
region with scattered colors demarks weaker input stimuli and
highlights trial-by-trial fluctuations in the spike probability. For
a better comparison of the differences in the firing properties
between a healthy and damaged neuron, the results from each of
the 11 trials with a healthy neuron were compared with the results
obtained with an increasing portion of membrane affected by AD,
in 10% increments. As shown in Figure 6B, the ratio between
spike probabilities for a neuron affected by AD falls down to zero
with the progression of the disease (blue region in Figure 6B).
This effect is quite dramatic for weaker synaptic inputs, and less
important for stronger inputs. To test whether and to what extent
a change in KA can restore the healthy conditions (i.e., those
plotted in Figure 6A), all simulations carried out under AD con-
ditions (Figure 6B) were repeated after a further 40% reduction
of KA. The resulting contour plot (Figure 6C) was very similar
to healthy conditions. We tested other different manipulations
that, in principle, might also give similar results, e.g., increas-
ing/decreasing the time constant of activation/inactivation, but
the results were not as profound as the change in the peak conduc-
tance (data not shown). These results suggest that a drug targeting
the KA current could be able to balance the depressing effect of
AD, in spite of the progression of the disease, maintaining the
spike probability close to that obtained in a normal neuron for
a wide range of synaptic input strengths.
OTHER POSSIBLE TREATMENTS
The 40% pharmacological change in KA discussed in the pre-
vious section may seem rather high. We therefore also tested
whether the same kind of improvement in firing properties can be
obtained with a combination of smaller changes in more than one
FIGURE 6 | Overall improvement of a KA-treatment. All contour plots
show, for each condition of synaptic weight and % of impaired surface, the
ratio between the average value of spike probability and its value under
control conditions (i.e., healthy neuron); healthy condition is represented by a
ratio around 1. (A) average ratio for 11 trials (differing each other for
redistribution of damaged neuronal area, synapses location and activation
time) under healthy conditions; (B) the ratio is decreased by AD, with a
stronger effect for higher portion of damaged membrane; (C) after
KA-treatment, the ratio is restored to a value around 1 (healthy conditions) for
a wide range of parameters.
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membrane or synaptic property. We were particularly interested
in changes affecting the peak synaptic conductances, because of
the plausible link between synaptic plasticity processes at a cel-
lular level and learning and memory at a behavioral level. We
found that a simultaneous 20% decrease of KA and a 22% peak
conductance increase of the synapses targeting the membrane
compartments affected by AD could give good results. Typical
curves for the spike probability and the contour plot for the ratio
with healthy conditions are reported in Figure 7. These results
show that even a moderate manipulation of KA could be able,
when coupled with a relatively small synaptic potentiation, to
restore the firing probability typical of a healthy neuron for a wide
range of inputs and the disease’s progression.
Finally, we tested a third treatment using a combination
of changes in synaptic strength (+22%) and Na conductance
(+30%), which could be useful when the disease has affected neu-
rons beyond the CA1 region, and where the KA may be much
lower and its manipulation less effective. The results are plotted
in Figure 8, and show that also this kind of change can give good
results for a wide range of parameters.
FIGURE 7 | Overall improvement after increasing the synaptic
conductance (+22%) and decreasing the KA current (−20%). (Left) Spike
probability for treated neuron (dotted lines) is compared with results from a
damaged neuron (solid lines), for three different value of synaptic input:
0.94 nS (green), 1 nS (black), 1.20 nS (red). Independently of synaptic strength
and increasing impaired surface the original spike probability
(control value corresponding to 0% of damaged neuronal area) is
restored; (Right) Normal conditions (i.e., ratio ≈ 1, yellow area)
are obtained for a wide range of synaptic inputs and affected
membrane area.
FIGURE 8 | Overall improvement after increasing the synaptic
conductance (+22%) and theNa current (+30%). (Left) Spike probability for
treated neuron (dotted lines) is compared with results from a damaged neuron
(solid lines), for three different value of synaptic input, as in Figure 7.
Independently of synaptic strength and increasing impaired surface, the
original spike probability (control value corresponding to 0% of damaged
neuronal area) is restored; (Right) Normal conditions (i.e., ratio ≈ 1, yellow area)
are obtained for a wide range of synaptic inputs and affected membrane area.
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DISCUSSION
AD is the most prevalent form of dementia, associated with
memory deficits and cognitive decline. Several emerging stud-
ies (LaFerla et al., 2007) point out that intracellular Aβ-peptides,
besides NFT or plaques, play a key role in the pathogenesis of
the disease. A number of experimental findings on Aβ effects
on ion channels or synaptic properties are available, but each
of them is focused on a single mechanism. To the best of our
knowledge, there are no experimental or computational stud-
ies that simultaneously consider the combined effect of several
membrane modifications caused by AD. For example, at the sin-
gle neuron level, Morse et al. (2010) examined in great detail
the effect of KA reduction (caused by Aβ) on a CA1 pyramidal
neuron. The results provided evidence that the thin oblique den-
drites in these neurons are the most sensitive to the changes in
the backpropagation of an action potential induced by the Aβ-
dependent KA blockade, which may result in an abnormal, and
possibly toxic, increase in calcium influx. At the network level,
Hasselmo (1997) used a network dynamic model to study the
phenomenon of runaway synaptic modification, showing that
it is linked to the spreading of neuropathology from the hip-
pocampus into neocortical structures and to memory deficits.
Other computational models focused only on synaptic dys-
function (Ruppin and Reggia, 1995; Horn et al., 1996; Rowan,
2012). More related to our work, Zou et al. (2011) investi-
gated the AD-induced theta rhythm abnormalities considering
the Aβ effects on four ionic channels (L-type Ca2+, KA, KDR,
and Ca2+-activated K+ current). However, the simulations car-
ried out included only one channel modification at a time.
They showed that only a KA reduction can induce the typical
increase in hippocampal-septal theta band power observed in AD
[Ponomareva et al. (2008)], suggesting that a pharmacological
action on this current could be a way to reduce the effects of Aβ
accumulation.
In our model we considered the combined effect of Aβ on
synapses and different ion channels. We were able to show how
and which mechanism can be the target of possible drugs for the
treatment of AD. The model predicts that a ≈20% increase of
KA or Na currents, combined with a similar increase in synaptic
conductance, may be sufficient to obtain a significant improve-
ment of the firing probability of a CA1 neuron. The possibility to
use KA channel manipulations in the attempt to ameliorate the
effects of AD is particularly intriguing. The peculiar distribution
of these channels in CA1 principal neurons (reviewed in Migliore
and Shepherd, 2002), expressed at an increasing dendritic density
with distance from the soma, suggests that a drug acting on KA
would be most effective only in these neurons, thus with lim-
ited collateral effects in other brain regions. On the contrary, a
drug acting on Na channels, which have a much wider distribu-
tion (Migliore and Shepherd, 2002), could be more effective when
the disease has also spread in other brain regions. The effect of
increasing the synaptic weight should also be stressed. It corre-
sponds to the physiological Long-Term Potentiation mechanism,
and it can be obtained by just “using” the synapses by refreshing
old memories to delay the effects of the degenerative disease. This
is consistent with experimental findings (Billings et al., 2007) sug-
gesting that learning slows the development of two brain lesions
related to AD. A conceptually similar result was also obtained
by Bentwich et al. (2011) with transcranial magnetic stimulation
combined with cognitive training.
A possible limitation of our approach is that Aβ-dependent
changes may initiate compensatory mechanisms involving ionic
and synaptic currents through homeostatic mechanisms that
could, in part, be responsible for the observed neuron proper-
ties (e.g., Horn et al., 1996; MacLean et al., 2005). Additional
processes not considered in this work, such as the effects of
Aβ on the interneurons responsible for feedforward inhibition,
may contribute to the overall effect on the spike threshold.
However, there is not enough information on the nature and
extent of these mechanisms in the current experimental models
of AD to implement a realistic model for them. A more detailed
analysis of their actual role was thus outside the scope of this
paper.
In conclusion, our model allowed us to take into account dif-
ferent experimental findings on the effects of Aβ accumulation,
providing new insight on how the combined interaction of dif-
ferent mechanisms can lead to overall effects that may be closer
to what happens in vivo. The model predictions on the possible
pharmacological treatments can be readily tested experimentally.
As new and more detailed experimental data will be available,
new, andmore specific actions can be modeled and tested to facil-
itate the long and expensive experimental investigations that are
currently and strongly limiting the development of new drugs in
this field.
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